TYPE-SPECIFIC SITE-DIRECTED HUMAN IMMUNODEFICIENCY VIRUS SEROLOGY NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


TYPE-SPECIFIC SITE-DIRECTED HUMAN IMMUNODEFICIENCY VIRUS SEROLOGY

Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 335-9, 1988.. Unique Identifier : AIDSLINE ICDB/89649778
Norrby E; Chiodi F; Biberfeld G; Mufson MA; Parks E; Lerner RA; Dept. of Virology, Karolinska Inst., Stockholm, Sweden

Abstract: Site-directed serology employing synthetic peptides is one means of improving the possibility of determining type-unique antibodies in a screening assay for HIV-1 or HIV-2. An enzyme-linked immunosorbent assay (ELISA) using such peptides has been developed that is specific for HIV-1. The test, designated the E32/E34 ELISA, uses synthetic antigens representing a portion of the transmembrane glycoprotein, gp41. Attempts to develop an ELISA that is specific for HIV-2 are described. A comparison of simian immunodeficiency virus and HIV sequence data for the transmembrane protein regions revealed a region of homology, and two peptides were synthesized that were homologous to E32 and E34. It was found that one of these (AlaIleGluLysTyrLeuGluAspGlnAlaGlnLeuAsnAlaTrpCysAlaPheArgGlnValC- ys) could be used to categorically separate sera of HIV-1-infected patients from those of HIV-2-infected patients. Correction of a small mistake in the original peptide (missing Gly between Trp and Cys) yielded an increase in both sensitivity and specificity of the ELISA. (8 Refs)
Keywords: Acquired Immunodeficiency Syndrome/*DIAGNOSIS/IMMUNOLOGY Amino Acid Sequence Animal AIDS Serodiagnosis/*METHODS Base Sequence Enzyme-Linked Immunosorbent Assay Human HIV/*IMMUNOLOGY HIV Antibodies/ANALYSIS HIV Antigens/IMMUNOLOGY HIV-1/IMMUNOLOGY HIV-2/IMMUNOLOGY SIV/IMMUNOLOGY Viral Envelope Proteins/IMMUNOLOGY MEETING PAPER

KWDacquiredimmunodeficiencysyndrome/KWDdiagnosis/immunologyaminoacidsequenceanimalaidsserodiagnosis/KWDmethodsbasesequenceenzyme-linkedimmunosorbentassayhumanhiv/KWDimmunologyhivantibodies/analysishivantigens/immunologyhiv-1/immunologyhiv-2/immunologysiv/immunologyviralenvelopeproteins/immunologymeetingpaper
890430
M8940681

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .